Clinical risk factors for adverse events in allopurinol users.

Abstract

Allopurinol, one of the most commonly used uric acid-lowering agents, can cause serious adverse events. To investigate the risk factors for allopurinol-induced adverse events, the authors enrolled 94 patients who developed allopurinol-induced adverse events and 378 controls who were randomly chosen from 1934 patients who used allopurinol but did not develop any adverse events in this retrospective case control study. Univariate analysis showed that patients who developed allopurinol-induced adverse events had more chronic kidney disease (46% vs 30%, P = .005), more hypertension (42% vs 30%, P = .036), less tumor lysis syndrome (P = .030), higher cholesterol (P = .013), and lower aspartate aminotransferase (P = .002) and alanine aminotransferase levels (P = .033) and more commonly used angiotensin receptor blockers (27% vs 15%, P = .007), colchicines (16% vs 5%, P = .010), or statins (19% vs 8%, P = .002) than those who did not. In multiple logistic regression analysis, the use of colchicines (odds ratio, 3.11; 95% confidence interval, 1.28-7.58; P = .012) and statins (2.10; 1.03-4.25; P = .041) was an independent risk factor predicting adverse events in allopurinol users. In conclusion, patients who use colchicine or statins are at significant risk for developing allopurinol-induced adverse events.

• Authors: Hee Jung Ryu, Ran Song, Hye Won Kim, Jin Hyun Kim, Eun Young Lee, Yun Jong Lee, Yeong Wook Song, Eun Bong Lee
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 53 Issue 2 Pg. 211-6 (Feb 2013) ISSN: 1552-4604 [Electronic] England
• PMID: 23436266 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2012.

Chemical References

• Gout Suppressants
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Allopurinol
• Colchicine

Topics

• Adult
• Aged
• Allopurinol (administration & dosage, adverse effects)
• Colchicine (administration & dosage)
• Drug-Related Side Effects and Adverse Reactions (epidemiology)
• Female
• Gout (drug therapy)
• Gout Suppressants (administration & dosage, adverse effects)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)
• Hyperlipidemias (drug therapy)
• Hypertension (drug therapy)
• Hyperuricemia (drug therapy)
• Male
• Middle Aged
• Renal Insufficiency, Chronic (drug therapy)
• Retrospective Studies
• Risk Factors
• Young Adult